Pafupifupi-khansa / chithandizo / mayesero azachipatala / matenda / merkel-cell / chithandizo

Chithandizo Chachipatala Mayeso a Merkel Cell Cancer

Mayesero azachipatala ndi maphunziro ofufuza omwe amakhudza anthu. Mayesero azachipatala pamndandandawu ndi a chithandizo cha khansa ya Merkel. Mayesero onse pamndandanda amathandizidwa ndi NCI.

Zambiri za NCI zokhudzana ndi mayesero azachipatala zimafotokozera mitundu ndi magawo am'mayesero ndi momwe amachitikira. Mayesero azachipatala amayang'ana njira zatsopano zotetezera, kuzindikira, kapena kuchiza matenda. Mungafune kuganizira zokhala ndi gawo pakuyesedwa kwachipatala. Lankhulani ndi dokotala wanu kuti akuthandizeni kusankha ngati mukuyenera.

Mayesero 1-25 a 32 1 2 Kenako>

Pembrolizumab Poyerekeza ndi Kuwonetsetsa Kusamalira Pochiza Odwala Omwe Ali Ndi Gawo Lathunthu la I-III Merkel Cell Cancer.

Gawo ili lachitatu limawunika momwe pembrolizumab imagwirira ntchito poyerekeza ndi momwe angathandizire pochiza odwala omwe ali ndi khansa ya cell I-III Merkel yomwe yachotsedwa kwathunthu ndi opareshoni (resected). Immunotherapy yokhala ndi ma monoclonal antibodies, monga pembrolizumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira. Malo: malo 286

Pembrolizumab yokhala kapena yopanda Stereotactic Therapy radiation Therapy pochiza odwala omwe ali ndi khansa yapakatikati kapena ya metastatic Merkel Cell

Kuyeserera kwa gawo lachiwirili komwe kumafufuza momwe pembrolizumab yokhala ndi kapena yopanda stereotactic radiation radiation imagwira ntchito pochiza odwala omwe ali ndi khansa ya cell ya Merkel yomwe yafalikira m'malo ena mthupi. Immunotherapy yokhala ndi ma monoclonal antibodies, monga pembrolizumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira. Mankhwala opatsirana pogwiritsa ntchito mphamvu ya stereotactic amagwiritsa ntchito zida zapadera kuti akhazikitse wodwala ndikupereka cheza ku zotupa mwatsatanetsatane. Njirayi imatha kupha maselo otupa ndi kuchepa pang'ono panthawi yayifupi ndikuwononga pang'ono minofu yabwinobwino. Kupereka pembrolizumab ndi stereotactic radiation radiation mankhwala atha kugwira ntchito bwino pochiza odwala omwe ali ndi khansa ya cell ya Merkel.

Malo: 246 malo

Kafukufuku Wofufuza za Immuno-Therapy Kafukufuku Wofufuza Chitetezo ndi Kuchita Bwino kwa Nivolumab, ndi Nivolumab Combination Therapy mu Zotupa zogwirizana ndi Virus

Cholinga cha kafukufukuyu kuti afufuze chitetezo cha nivolumab, ndi nivolumab kuphatikiza mankhwala, kuti athandize odwala omwe ali ndi zotupa zokhudzana ndi ma virus. Ma virus ena amadziwika kuti amatenga gawo pakapangidwe kazotupa ndikukula. Kafukufukuyu adzafufuza zotsatira zamankhwalawa, kwa odwala omwe ali ndi zotupa zotsatirazi: - Khansa ya canal ya Canal-Osalembetsanso chotupachi - Khansa ya pachibelekero - Epstein Barr Virus (EBV) khansa ya m'mimba yabwino-Osatinso izi Mtundu wa chotupa - Khansa ya Merkel - Khansa ya Penile-Kulembetsanso mtundu uwu wa khansa - Khansa ya m'mimba ndi ya vulvar-Simulembetsanso chotupachi - Khansa ya Nasopharyngeal - Simulembetsanso chotupachi - Khansa ya Mutu ndi Khosi - Simulembetsanso chotupachi

Malo: malo 10

Kafukufukuyu Akuwunika KRT-232, Novel Oral Small Molecule Inhibitor ya MDM2, yothandizira odwala omwe ali nawo (p53WT) Merkel Cell Carcinoma Omwe Ataya Anti-PD-1 / PD-L1 Immunotherapy

Kafukufukuyu akuwunika KRT-232, buku laling'onoting'ono laling'ono la molekyulu yoletsa MDM2, yothandizira odwala omwe ali ndi Merkel Cell Carcinoma (MCC) omwe alephera kulandira chithandizo ndi anti-PD-1 imodzi kapena anti-PD-L1 immunotherapy. Kuletsa kwa MDM2 ndi njira yatsopano yochitira mu MCC. Kafukufukuyu ndi Phase 2, Open-Label, Single-Arm Study ya KRT-232 mwa Odwala omwe ali ndi p53 Wild-Type (p53WT) Merkel Cell Carcinoma

Malo: Malo 11

Adjuvant Avelumab ku Merkel Cell Cancer

Kafukufukuyu adafufuza momwe avelumab imagwirira ntchito pochiza odwala khansa ya Merkel yomwe yafalikira ku ma lymph node ndikuchitidwa opaleshoni popanda kapena radiation. Ma antibodies a monoclonal, monga avelumab, amatha kulimbikitsa chitetezo cha mthupi komanso kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira.

Malo: malo 10

QUILT-3.055: Kafukufuku wa ALT-803 Ophatikizana Ndi PD-1 / PD-L1 Checkpoint Inhibitor mwa Odwala Omwe Ali ndi Khansa Yapamwamba

Ili ndi gawo lachiwiri la IIb, dzanja limodzi, multicohort, lotseguka lotsegulira ma ALT-803 limodzi ndi PD-1 / PD-L1 checkpoint inhibitor yovomerezedwa ndi FDA mwa odwala khansa omwe apita patsogolo kutsatira poyankha koyamba ku chithandizo ndi PD-1 / PD-L1 checkpoint inhibitor therapy. Odwala onse adzalandira chithandizo chophatikizira cha PD-1 / PD-L1 checkpoint inhibitor kuphatikiza ALT-803 mpaka 16. Kuzungulira kulikonse kumakhala milungu isanu ndi umodzi. Odwala onse adzalandira ALT-803 kamodzi pamasabata atatu. Odwala alandiranso cholembera cholembera chomwe adalandira panthawi yomwe adalandira chithandizo cham'mbuyomu. Kuwunika kwa ma Radiologic kumachitika kumapeto kwa nthawi iliyonse yamankhwala. Chithandizo chidzapitilira kwa zaka ziwiri, kapena mpaka wodwalayo atatsimikizira kuti matenda akupita patsogolo kapena kawopsedwe kosavomerezeka, atasiya kuvomereza, kapena ngati Wofufuzayo akuwona kuti sizofunikiranso wodwalayo kupitiliza kulandira chithandizo. Odwala adzatsatiridwa chifukwa cha kupita patsogolo kwa matenda, chithandizo chamankhwala cham'mbuyomu, komanso kupulumuka miyezi 24 yapitayi poyendetsa mankhwala oyamba.

Malo: Malo 9

Kafukufuku wa NKTR-262 Mgwirizano Ndi NKTR-214 komanso NKTR-214 Plus Nivolumab mwa Odwala Omwe Ali Ndi Matenda Otukuka Kapena Amatenda Olimba Kwambiri.

Odwala alandila intra-tumoral (IT) NKTR-262 m'masabata atatu azachipatala. Pakati pa gawo loyesa gawo la gawo 1, NKTR-262 iphatikizidwa ndi kayendedwe kabwino ka bempegaldesleukin. Pambuyo pakudziwitsa za Phase 2 mlingo (RP2D) wa NKTR-262, pakati pa 6 ndi 12 odwala atha kulembetsa ku RP2D kuti apitilize kudziwika ndi chitetezo ndi kulolerana kwa kuphatikiza kwa NKTR 262 kuphatikiza bempegaldesleukin (doublet) kapena NKTR 262 kuphatikiza bempegaldesleukin kuphatikiza nivolumab (triplet) mu Cohorts A ndi B, motsatana. Mu gawo lokulitsa la gawo la 2, odwala adzathandizidwa ndi maphatidwe awiri kapena atatu mumayendedwe obwereranso / obwezeretsa komanso njira zamankhwala zoyambilira.

Malo: malo 14

Kafukufuku wa INCMGA00012 mu Metastatic Merkel Cell Carcinoma (POD1UM-201)

Cholinga cha phunziroli ndikuwunika zochitika zamatenda ndi chitetezo cha INCMGA00012 mwa omwe ali nawo omwe ali ndi kachilombo ka Merkel cell carcinoma (MCC).

Malo: Malo 8

PEN-221 ku Somatostatin Receptor 2 Yofotokoza Khansa Yapamwamba Kuphatikiza Khansa ya Neuroendocrine ndi Khansa Yaing'ono Yam'mapapo

Protocol PEN-221-001 ndiwotseguka, wowerengeka wa Phase 1 / 2a wowunika PEN-221 mwa odwala omwe ali ndi SSTR2 ofotokoza zam'mimba za gastroenteropancreatic (GEP) kapena lung kapena thymus kapena zotupa zina za neuroendocrine kapena khansa yaying'ono yamapapo yam'mapapo kapena cell yayikulu neuroendocrine carcinoma wa m'mapapo.

Malo: Malo 7

Phunziro 1/2 Phunziro la Katemera wa In Situ Ndi Tremelimumab ndi IV Durvalumab Plus PolyICLC mwa Omwe Ali ndi Khansa Yapamwamba, Yoyeserera, Yofiyira

Uwu ndi kafukufuku wotseguka, wowerengeka wa Gawo 1/2 la anti-CTLA-4, tremelimumab, ndi anti-PD-L1, durvalumab (MEDI4736), kuphatikiza chotupa cha microenvelo (TME) modulator polyICLC, agonist wa TLR3, m'mitu yomwe ili ndi khansa yapamwamba, yoyezeka, yomwe imapezeka ndi khansa.

Malo: 6 malo

Intratumoral AST-008 Kuphatikiza ndi Pembrolizumab mwa Odwala Omwe Ali Ndi Zotupa Zolimba

Ili ndi gawo 1b / 2, lotseguka, kuyesa kosiyanasiyana komwe kumapangidwira kuyesa chitetezo, kulolerana, pharmacokinetics, pharmacodynamics ndikuwunika koyambirira kwa jakisoni wa AST-008 wokha komanso kuphatikiza kwa pembrolizumab ya intravenous mwa odwala omwe ali ndi zotupa zolimba. Gawo 1b la mayeserowa ndi kafukufuku wowonjezeka wa 3 + 3 wowunika kuchuluka kwa mlingo wa AST-008 woperekedwa ndi pembrolizumab. Gawo 2 ndi gulu lowonjezera kuti lipitilize kuyesa AST-008 yoperekedwa limodzi ndi pembrolizumab mwa anthu ena kuti apereke kuyerekezera koyambirira kwa odwala omwe adalandira kale osayankha anti-PD-1 kapena anti-PD-L1 antibody mankhwala.

Malo: Malo 7

Kuyesedwa kwa Intratumoral jakisoni wa TTI-621 mwa Ophunzira Omwe Ali Ndi Matenda Olimba Obwezerezedwanso Ndi Otsutsa ndi Mycosis Fungoides

Izi ndizowerengeka, zotseguka, gawo 1 kafukufuku wopangidwa kuti ayesere jakisoni wa TTI-621 m'mitu yomwe yabwereranso ndikupanga zotupa zolimba zomwe zimapezeka mosavuta kapena mycosis fungoides. Kafukufukuyu azachitika m'magulu awiri osiyana. Gawo 1 ndilo gawo la Dose Escalation ndipo Gawo 2 ndi gawo la Kukula kwa Dose. Cholinga cha phunziroli ndikuwonetsa momwe chitetezo cha TTI-621 chikuwonekera komanso kudziwa kuchuluka kwa TTI-621. Kuphatikiza apo, chitetezo ndi antitumor ntchito za TTI-621 ziwunikidwa kuphatikiza ndi othandizira ena a khansa kapena radiation.

Malo: 5 malo

Kafukufuku wa RP1 Monotherapy ndi RP1 Mgwirizano Ndi Nivolumab

RPL-001-16 ndi Phase 1/2, lotseguka chizindikiro, kuchuluka kwa kuchuluka ndi kufalikira kwachipatala cha RP1 chokha komanso kuphatikiza nivolumab m'maphunziro akulu omwe ali ndi zotupa zolimba komanso / kapena zotsutsa, kuti adziwe kuchuluka kwakulekerera (MTD) ndi mlingo woyenera wa Phase 2 (RP2D), komanso kuwunika momwe ntchito ikuyendera.

Malo: 6 malo

Talimogene Laherparepvec yokhala ndi kapena yopanda Hypofractionated Radiation Therapy pochiza Odwala omwe ali ndi Metastatic Melanoma, Merkel Cell Carcinoma, kapena Zotupa Zina Zolimba

Kuyeserera kwachiwiri kwa gawo lachiwirili kumafufuza zoyipa za talimogene laherparepvec ndikuwona momwe zimagwirira ntchito kapena popanda hypofractionated radiation pochiza odwala omwe ali ndi khansa ya pakhungu, Merkel cell carcinoma, kapena zotupa zina zolimba zomwe zafalikira m'malo osayenera kuchotsedwa opaleshoni. . Mankhwala omwe amagwiritsidwa ntchito mu immunotherapy, monga talimogene laherparepvec, atha kulimbikitsa chitetezo cha mthupi kulimbana ndi zotupa. Mankhwala opatsirana pogwiritsa ntchito mankhwalawa amapereka mlingo waukulu wa mankhwalawa poizoni kwa kanthawi kochepa ndipo amatha kupha ma cell ambiri a chotupa komanso kukhala ndi zotsatirapo zochepa. Sizikudziwika ngati kupereka talimogene laherparepvec kapena popanda mankhwala opatsirana pogwiritsa ntchito mankhwalawa kungathandize kwambiri pochiza odwala omwe ali ndi khansa yapakhungu yotchedwa melanoma, Merkel cell carcinoma, kapena zotupa zolimba.

Malo: malo atatu

FT500 ngati Monotherapy komanso Kuphatikiza ndi Immune Checkpoint Inhibitors Omwe Ali Ndi Zotupa Zolimba

FT500 ndi pashelefu, yopangidwa ndi NKSC yochokera ku iPSC yomwe imatha kuthana ndi chitetezo chokwanira komanso chosinthika, ndipo imatha kuthana ndi njira zingapo zotetezera chitetezo cha chitetezo cha mthupi (ICI). Zambiri zam'mbuyomu zimapereka umboni wokwanira wotsimikizira kufufuzidwa kwa FT500 ngati monotherapy komanso kuphatikiza ICI m'mitu yomwe ili ndi zotupa zolimba.

Malo: malo atatu

Tacrolimus, Nivolumab, ndi Ipilimumab pochiza Opatsirana a Impso Omwe Ali ndi Khansa Yosasinthika Yosasunthika kapena Metastatic

Gawo ili loyesa ndimayesa momwe tacrolimus, nivolumab, ndi ipilimumab zimagwirira ntchito pochiza omwe amalandira impso omwe ali ndi khansa yomwe singathe kuchotsedwa ndi opareshoni (yosasunthika) kapena yafalikira m'malo ena mthupi (metastatic). Tacrolimus ikhoza kuyimitsa kukula kwa zotupa mwa kulepheretsa michere ina yofunikira pakukula kwamaselo. Immunotherapy yokhala ndi ma monoclonal antibodies, monga nivolumab ndi ipilimumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira. Kupereka tacrolimus, nivolumab, ndi ipilimumab zitha kugwira ntchito bwino pochizira omwe amalandira impso ndi khansa poyerekeza ndi chemotherapy, opaleshoni, radiation radiation, kapena njira zochiritsira.

Malo: malo awiri

Nivolumab ndi Ipilimumab omwe alibe kapena opanda Stereotactic Therapy radiation Therapy pochiza odwala omwe ali ndi khansa yaposachedwa kapena Gawo IV Merkel Cell Cancer.

Kafukufukuyu adafufuza momwe nivolumab ndi ipilimumab omwe ali ndi kapena opanda stereotactic radiation radiation amagwira ntchito pochiza odwala khansa ya Merkel cell yomwe yabwerera kapena gawo IV. Immunotherapy yokhala ndi ma monoclonal antibodies, monga nivolumab ndi ipilimumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira. Mankhwala opatsirana pogwiritsa ntchito mphamvu ya stereotactic amagwiritsa ntchito zida zapadera kuti akhazikitse wodwala ndikupereka cheza ku zotupa mwatsatanetsatane. Njirayi imatha kupha maselo otupa ndi kuchepa pang'ono panthawi yayifupi ndikuwononga pang'ono minofu yabwinobwino. Kupereka nivolumab ndi ipilimumab kapena popanda stereotactic radiation radiation ingagwire bwino ntchito pochiza odwala khansa ya Merkel cell.

Malo: malo awiri

Pembrolizumab ndi Radiation Therapy Yothandizira Matenda a Metastatic Merkel Cell Carcinoma

Gawo ili lachiwiri limawunika zoyipa zake komanso momwe pembrolizumab ndi radiation radiation zimagwirira ntchito pochiza odwala omwe ali ndi Merkel cell carcinoma yomwe yafalikira m'malo ena mthupi (metastatic). Immunotherapy yokhala ndi ma monoclonal antibodies, monga pembrolizumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira. Thandizo la radiation limagwiritsa ntchito ma x-ray amphamvu kupha ma cell a chotupa ndikuchepetsa zotupa. Kupereka pembrolizumab ndi radiation radiation kumatha kukulitsa phindu la pembrolizumab.

Kumalo: Stanford Cancer Institute Palo Alto, Palo Alto, California

Kafukufuku wa LY3434172, PD-1 ndi PD-L1 Bispecific Antibody, mu Advanced Cancer

Cholinga chachikulu cha kafukufukuyu ndikuwunika chitetezo ndi kulolerana kwa mankhwala ophunzirira a LY3434172, anti-PD-1 / PD-L1 bispecific antibody, mwa omwe ali ndi zotupa zolimba.

Kumalo: MD Anderson Cancer Center, Houston, Texas

Therapy Therapy (Tumor infiltrating Lymphocytes) yothandizira khansa yapafupi, metastatic, kapena recurrent solid cancer

Gawo lachiwiri lachiyeso limafufuza momwe ma cell (omwe ali ndi chotupa cholowerera ma lymphocyte) amagwirira ntchito pochiza khansa yolimba yomwe yafalikira kumatenda oyandikira kapena ma lymph node (akumaloko), yafalikira mbali zina za thupi (metastatic), kapena bwererani (mobwerezabwereza). Kuyesaku kumaphatikizapo kutenga maselo otchedwa ma lymphocyte (mtundu wa khungu loyera lamagazi) kuchokera ku zotupa za odwala, kuwakulitsa mu labotale mwaunyinji, kenako ndikupereka ma cellwo kwa wodwalayo. Maselowa amatchedwa chotupa cholowerera ma lymphocyte ndipo mankhwalawa amatchedwa cell therapy. Kupereka mankhwala a chemotherapy maselo asanapondereze chitetezo cha mthupi kwakanthawi kuti zithetse mwayi woti ma cell olimbana ndi chotupacho azitha kukhala mthupi. Kupereka aldesleukin pambuyo poyang'anira maselo kumatha kuthandiza ma cell olimbana ndi chotupacho kukhalabe ndi moyo nthawi yayitali.

Kumalo: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

Nivolumab ndi Therapy Radiation Therapy kapena Ipilimumab ngati Adjuvant Therapy pochiza Odwala omwe ali ndi khansa ya Merkel Cell

Gawo ili loyeserera limafufuza zoyipa zake komanso momwe nivolumab imagwirira ntchito ikaperekedwa limodzi ndi radiation radiation kapena ipilimumab ngati chithandizo chothandizira pochiza odwala omwe ali ndi khansa ya cell ya Merkel. Immunotherapy yokhala ndi ma monoclonal antibodies, monga nivolumab ndi ipilimumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira. Thandizo la radiation limagwiritsa ntchito ma x-ray amphamvu, cheza cha gamma, ma neutroni, ma proton kapena zinthu zina kupha ma cell a chotupa ndikuchepetsa zotupa. Kupereka nivolumab ndi radiation radiation kapena ipilimumab pambuyo pa opaleshoni kumatha kupha maselo aliwonse otupa.

Kumalo: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Pembrolizumab (MK-3475) ngati Therapy Yoyamba ya Advanced Merkel Cell Carcinoma (MK-3475-913)

Ili ndi dzanja limodzi, lotseguka, lotseguka, logwira ntchito moyenera, komanso lotetezeka pembrolizumab mwa omwe akutenga nawo gawo mwa achikulire komanso ana omwe ali ndi Merkel Cell Carcinoma (MCC) omwe sanalandire chithandizo. Cholinga chachikulu cha mayeserowa ndikuwunika momwe anthu angayankhire, monga momwe kuwunikiranso komwe kumayang'aniridwa poyang'ana poyeserera pamavuto olimba a 1.1 (RECIST 1.1) adasinthidwa kuti atsatire zilonda zopitilira 10 komanso zotupa za 5 chiwalo chilichonse, kutsatira pembrolizumab.

Kumalo: Laura ndi Isaac Perlmutter Cancer Center ku NYU Langone, New York, New York

Maselo Omwe Amasinthidwa Ndi Gene (FH-MCVA2TCR) Pochiza Odwala Omwe Ali ndi Metastatic kapena Unresectable Merkel Cell Cancer

Gawoli I / II likuwunika zoyipa zamaselo amthupi otetezedwa (FH-MCVA2TCR) ndikuwona momwe amagwirira ntchito pochiza odwala khansa ya Merkel yomwe yafalikira mbali zina za thupi (metastatic) kapena zomwe sizingatheke kuchotsedwa ndi opaleshoni (yosasunthika). Kuyika jini yomwe yapangidwa mu labotale m'maselo achitetezo kumathandizira kuti thupi lizitha kulimbana ndi khansa ya cell ya Merkel.

Kumalo: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

Phunziro la Chitetezo ndi Kuleza Mtima kwa INCAGN02390 mu Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.

Location: Hackensack University Medical Center, Hackensack, New Jersey

Abexinostat and Pembrolizumab in Treating Patients with MSI-High Locally Advanced or Metastatic Solid Tumors

Gawo ili loyeserera limafufuza za mlingo wabwino ndi zoyipa za abexinostat ndi momwe imagwirira ntchito limodzi ndi pembrolizumab pochiza odwala omwe ali ndi zotupa za microsatellite instability (MSI) zomwe zafalikira kumatenda oyandikira kapena ma lymph node (akumaloko) kapena malo ena m'thupi (metastatic). Abexinostat ikhoza kuyimitsa kukula kwa zotupa mwa kulepheretsa michere ina yofunikira pakukula kwamaselo. Immunotherapy yokhala ndi ma monoclonal antibodies, monga pembrolizumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira. Kupatsa abexinostat ndi pembrolizumab kumatha kugwira ntchito bwino pochiza odwala omwe ali ndi zotupa zolimba.

Kumalo: UCSF Medical Center-Mount Ziyoni, San Francisco, California

1 2 Kenako>